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ABSTRACT 
The base excision repair (BER) pathway is an 
important DNA repair pathway and is essential for 
immune responses. In fact, it regulates both the 
antigen-stimulated somatic hypermutation (SHM) 
process and plays a central function in the process 
of class switch recombination (CSR). For both 
processes, a central role for apurinic/apyrimidinic 
endonuclease 1 (APE1) has been demonstrated. 
APE1 acts also as a master regulator of gene 
expression through its redox activity. APE1’s 
redox activity stimulates the DNA-binding activity 
of several transcription factors, including NF-B 
and a few others involved in inflammation and in 
immune responses. Therefore, it is possible that 
APE1 has a role in regulating the CSR through its 
function as a redox coactivator. The present study 
was undertaken to address this question. Using the 
CSR-competent mouse B cell line CH12F3 and a 
combination of specific inhibitors of APE1’s redox 
(APX3330) and repair (compound #3) activities, 
APE1-deficient or -reconstituted cell lines 
expressing redox-deficient or endonuclease-
deficient proteins, and APX3330-treated mice, we 
determined the contributions of both endonuclease 
and redox functions of APE1 in CSR. We found 
that APE1’s endonuclease activity is essential for 
IgA-class switch recombination. We provide 
evidence that the redox function of APE1 appears 
to play a role in regulating CSR through the 
interleukin-6 signaling pathway and in proper IgA 
expression. Our results shed light on APE1’s redox 
function in the control of cancer growth through 
modulation of the IgA CSR process. 
 
Antigen-dependent B cell activation is a 
dynamically integrated cascade of cell signaling 
events. It requires accessory signals that can come 
either from an armed helper T cell or, in some 
cases, directly from microbial constituents. 
Downstream consequences of transduced signals 
are the initiating of genomic rearrangement that 
induces somatic hypermutation (SHM) (1) and a 
class switch recombination (CSR) that switches the 
CH region (1). Both immunoglobulin SHM and 
CSR are essential mechanisms for the generation 
of a high affinity, adaptive humoral immune 
response, require transcription and are dependent 
on the activation-induced cytidine deaminase 
(AID), which converts cytosine to uracil and also 
contributes to the formation of requisite ssDNA 
substrates. Both processes engage activities of 
normal cellular base excision repair (BER) and 
mismatch repair (MMR), converting AID cytidine 
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deamination lesions to mutational and/or double 
strand breaks (DSB) outcomes.  
The BER pathway is a highly conserved pathway 
from bacteria to humans and is responsible for the 
maintenance of genome stability through repairing 
DNA damage caused by oxidative stress, ionizing 
radiation (IR) and chemotherapy treatments. These 
damages are typically non-distorting alkylated and 
oxidized bases, as well as single-strand breaks. 
However, the enzymes involved in BER also take 
part in a variety of apparently unrelated cellular 
functions related to gene expression mechanisms 
(2). 
The role of BER enzymes, in SHM and CSR, 
strongly depends on cross-talk between each single 
protein partners and is finely tuned by the 
expression levels of each protein and by specific 
regulated post-translational modifications, such as 
phosphorylation of Ser38 in AID protein (3, 4). 
APE1, which is the unique Apurinic/apyrimidinic 
endonuclease in mammalian cells, is responsible 
for the recognition and cleavage of the abasic sites 
generated spontaneously or by the action of 
specialized glycosylase enzymes (2). APE1 
deficiency, while not affecting AID-induced S-
region break formation, impairs both the 
recruitment of Ku80 to the S region and the 
synapse formation between Sµ and Sα (5). APE1 
endonuclease activity likely removes 3′-tyrosyl 
residues from the DNA end after topoisomerase 1 
(Top1) cleavage and Top1-cc degradation, which 
is essential to efficient recombination of broken S 
regions. Additionally, S regions are subjected to a 
high rate of transcription driven by cytokine-
inducible promoters, which regulates the CSR 
process.  
Besides serving in a crucial role in the 
maintenance of genome stability through its 
endonuclease activity, APE1 also acts as a master 
regulator of cellular response regulating gene 
expression through its redox signaling activity (6–
8). APE1 redox-mediated stimulation of the DNA-
binding activity of several transcription factors 
(TFs) (for this reason APE1 is also called Ref-1; 
redox effector factor 1) including STAT3, nuclear 
factor kappa B (NF-ĸB), AP-1, HIF-1 p53 and 
others affecting the promotion of tumor growth and 
progression as well as the inflammation process. 
APE1 is a unique nuclear redox-signaling factor 
bearing seven Cys residues. Three of the Cys 
residues, C65, C93, and C99, are sufficient for its 
redox activity and the mechanism for its redox 
activity has been characterized in detail and 
involves a redox cycle with potential formation of 
intermolecular disulfide bonds with the protein 
target (9–14). While C65 acts as the nucleophilic 
cysteine, C93 and C99 likely play roles in resolving 
disulfide bonds that are formed in APE1 upon 
oxidation. The redox-active Cys residues are 
clustered in one of the two  -sheets that make up 
the -sandwich fold of the APE1 structure. C65 
and C93 are located within adjacent strands in the 
middle of one of the  -sheets within APE1, albeit 
positioned on opposite sides of the sheet, while 
C99 is located within a connecting loop region. 
Structural studies demonstrated that APE1 exists in 
both native and partially unfolded conformations. 
Thioredoxin (TRX) is involved in the redox cycle 
through the formation of a large complex upon 
mixed disulfide bond with partially unfolded APE1 
(9). Therefore, the partially unfolded state of APE1 
represents the redox active intermediate of the 
enzyme. The unique mechanism of action of the 
most well characterized APE1 redox inhibitor, i.e. 
APX3330 (formerly E3330), is based on APX3330 
interacting with the locally unfolded state of APE1. 
APX3330 stabilizes this unfolded state causing 
buried Cys residues such as C65 and C93 to be 
exposed and facilitates disulfide bond formation. 
This disulfide bond formation results in an 
inactivation of APE1 and a decrease in interaction 
with downstream transcriptor factors effectively 
causing them to be inactive (10, 12, 13). Fine-
tuning of the different APE1 functions is affected 
by numerous post-translational modifications as 
well as by the protein interactome (15). 
It can be speculated that a role for APE1 in 
regulating the CSR through its function as a 
transcriptional activator could account for the 
remaining CSR activity observed in APE1-
endonuclease activity deficient cells (16). While 
APE1 endonuclease activity is important for CSR, 
it is dispensable for SHM and AID-induced DNA 
breaks and may function as a DNA end-processing 
enzyme to facilitate the joining of broken ends 
during CSR (5). Notably, the mechanism by which 
AID is targeted to its substrates is of great interest, 
given the potentially deleterious consequences of 
AID’s mutagenic activity (17). Off-target AID 
activities can activate oncogenes via mutations or 
translocations and, thereby, contribute to B cell as 
well as in other cancers. Cumulating evidence 
demonstrates that APE1 may represent a new 
signaling node in cancer and other diseases through 
a function in RNA metabolism, including miRNA 
and RNA processing (6).  
Since APE1 has emerged as a promising target for 
cancer therapy, great efforts have been directed, by 
different groups including ours, to develop specific 
small molecules inhibitors of the different 
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APE1functions. Actually, both DNA repair 
(compound #3) (18), redox (i.e. APX3330) (10, 11, 
19–22) and inhibitors of the APE1/NPM1 
interaction (i.e. spiclomazine, fiduxosin, 
SB206553) (23) are available to dissect the specific 
role of each function in controlling multiple 
biological processes by APE1 (6). APX3330 has 
been shown to be specific for inhibition of APE1 
redox function and blocking the activity of redox-
regulated transcription factors. Additionally, 
APX3330 has entered phase I clinical trials which 
are concluding (NCT03375086) (24–26). 
Furthermore, the blockade of APE1’s redox 
activity has been shown to reduce growth-
promoting, inflammatory and anti-apoptotic 
activities in cells (27–29). 
Importantly, the SHM apparatus, as well as the 
rate of mutation, can be influenced by the impact 
of radio- and chemo-therapeutic regimens on DNA 
damage, genome stability and on gene expression. 
The maintenance of DNA integrity through repair 
is critical for genetic stability and limiting the 
deleterious effects on the immune system (30). 
Increased expression of the central BER protein 
APE1 confers resistance to some oxidative and 
alkylating agents as well as IR (7). Therefore, the 
role of BER in controlling the physiologic function 
of the immune system is central, under normal and 
under genotoxic conditions, such as those 
represented by chemotherapy and radiotherapy 
regimens. 
In the present study, we analyzed the 
contribution of both the DNA repair endonuclease 
and redox-signaling functions of APE1 in CSR 
using different APE1 inhibitors and APE1 DNA-
repair and redox-defective mutants. We confirmed 
that the endonuclease function of APE1 is essential 
for IgA-class switch recombination. Interestingly, 
and for the first time, we provide evidence that the 
redox function of the protein also plays an 
important role in regulating CSR through the IL-6 
signaling pathway and proper IgA expression. 
 
Results 
APE1 redox and endonuclease inhibitors reduce 
class switch recombination in CH12F3 cells. 
In these studies, we took advantage of the CSR-
competent mouse B cell line CH12F3, which 
undergoes robust IgA switching in response to 
appropriate stimuli. In order to elucidate which 
function of APE1 is important for CSR, CH12F3 
cells were pretreated with specific APE1 inhibitors 
and then induced to CSR. Two different inhibitors 
were employed (Fig. 1): APX3330, a well-known 
inhibitor of APE1 redox signaling activity that does 
not affect the DNA repair activity, and the small 
molecule inhibitor compound 3 (#3) (18), that 
inhibits the APE1 endonuclease activity without 
hampering APE1 redox function (19). Both 
inhibitors were initially evaluated for toxicity to 
determine the appropriate sub-toxic concentrations 
and to exclude off-target effects (Fig. S1). Cell 
viability was determined to be unaffected by after 
treating the cells up to 50 M of APX3330, while 
some cell toxicity was observed at the highest 
tested dose of #3 (1 M). The efficacy of 0.2 M 
of #3 inhibitor, as well as the expression levels of 
APE1, were also tested (Fig. S2). The doses of 0.2 
M of #3 and 50 M of APX3330 were 
subsequently used in which APE1 protein 
expression remained unaffected. 
For the CSR experiment, CH12F3 were pre-
incubated with 50 M APX3330, 0.2 M of #3 and 
a combination of both drugs for 30 minutes, then 
induced to CSR through the addition of the anti-
CD40 antibody and recombinant IL-4 and TGF- 
(CIT). After 72 hours, cells were harvested and 
analyzed for surface IgA expression (Fig. 2A and 
B). Unstimulated CH12F3 cells, cultured in a 
normal medium, were used as negative control 
(CIT(-)). Under CSR conditions, and in the absence 
of the inhibitors, the percentage of IgA-positive 
cells reached 32% versus 7% for the unstimulated 
CH12F3, while the overall IgA-class switching in 
cells treated with #3 and APX3330 was reduced 
with respect to untreated cells (20% and 17% of 
IgA+ cells in presence of #3 and APX3330 
respectively). Lower doses of APX3330 and #3 
were also tested, but as shown in Table 1, the 
observed reduction of IgA expression was less 
pronounced than that obtained with 50 M 
APX3330 and 0.2 M of #3. The higher dose of #3 
(1M) demonstrated the best results in terms of 
IgA reduction (Table 1), but is associated with a 
toxic effect (Supplemental Figure S1A).  
Interestingly, when APE1 inhibitors were used in 
combination, a greater inhibitory effect was 
observed, resulting in less than 10% of CH12F3 
cells expressing IgA. This inhibitory effect was 
confirmed by evaluation of IgA released in the cells 
supernatants especially when APX3330 and #3 
were used in combination (Fig. 2C and Fig. S3A). 
The effect of both APE1 inhibitors on CSR was not 
due to toxicity or hampered proliferation at the 
doses employed in the CSR experiments, as 
determined by viable cell counting (Fig. 2D) and 
by evaluation of viable and dead cells following 72 
hours of a challenge with both inhibitors (Fig. 2E). 
Together, these data indicate that both the 
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endonuclease and the redox activities of APE1 
exert a role in CSR. 
 
Expression of APE1-redox and -endonuclease 
defective mutants differently affect class switch 
recombination in CH12F3 cells 
In order to investigate the dual role of APE1 
through an alternative approach and in order to 
exclude possible off-target effects by the two 
inhibitor compounds, we expressed APE1 wild-
type and its loss-of-function mutant forms (either 
redox- or DNA-repair deficient) in the CH12F3 
cells genetically ablated of Ape1 gene, previously 
generated by Masani et al. (16). These experiments 
allow dissecting the dual role of APE1 in CSR 
avoiding the confounding contribution of the 
endogenous APE1 protein. In particular, we 
employed CH12F3 APE1+/+/ and CH12F3 
APE1// cells containing two and zero copies of 
APE1 gene, resulting from one and three cycles of 
gene targeting, respectively (Fig. S4). As expected, 
the absence of APE1 completely impaired the 
capacity of the CH12F3 cells to undergo CSR, 
while the CH12F3 APE1+/+/ cells were still able to 
switch towards IgA (Fig. 3A and B) and to secrete 
the immunoglobulin in the cell supernatant (Fig. 
3C). 
Under CSR condition, the exposure to APX3330 
and the #3 inhibitors reduced the expression of IgA 
in CH12F3 APE1+/+/, while the CH12F3 APE1// 
cells were still negative for IgA expression (Fig. S5 
A, B). Annexin/PI staining ruled out a negative 
effect on the cellular viability by the inhibitors 
(Fig. S5C, D).  
Subsequently, CH12F3 APE1+/+/ and CH12F3// 
cells were transfected with a nuclease-defective  
(APE1E96A) (31) and a redox-defective (APE1C65S) 
APE1(32). To minimize the potential variation 
among samples, wild-type and mutant APE1 
constructs were cloned in frame with a Green 
Fluorescent Protein sequence to allow expression 
of the GFP-tagged protein. In this way, when 
performing FACS analysis, IgA-positive cells were 
investigated among the whole GFP-positive 
population (Fig. S6A). Cytofluorimetric analysis of 
the GFP-positive cells showed that, upon transient 
transfection, wild-type APE1 (APE1WT) and 
mutant transgenes were similarly expressed in both 
CH12F3 APE1+/+/ and CH12F3 APE1// cells 
(Fig. S6B, C). 
Data in figure 2D shows that transfection with 
plasmids containing the APE1WT as well as 
APE1C65S and APE1E96A mutants did not 
significantly modify the CSR response of the 
CH12F3 APE1+/+/ cells, being similar to that 
observed with the empty vector both in terms of 
surface IgA expression (Fig. 3D and E) and of IgA 
secretion (Figure 3F). 
On the other hand, re-expression of APE1WT in 
CH12F3 APE1// restored their IgA switching 
ability, as shown by increased IgA positivity from 
0.4 to 3.98%, a ten-fold increase. Notably, 
transfections with both APE1 mutant forms only 
mildly restored the CSR capacity of APE1-null 
cells (Fig. 3G and H). The ELISA assay of 
supernatant-released IgA confirmed the 
cytofluorimetric data obtained (Fig. 3I).   
These results demonstrate that the redox-signaling 
activity of APE1 is required for optimal CSR.   
 
APX3330 impairs the production of IL-6 that is 
crucial for the efficient class switch 
recombination 
APE1 redox activity is fundamental in immune 
cells for the production of several cytokines, whose 
expression is regulated by redox-sensitive 
transcription factors, such as NF-B and STAT3 
(24). Among these cytokines, IL-6 is primarily 
involved in B cell proliferation and cell function 
(33). 
In order to test whether the redox activity of 
APE1 in CSR was mediated by IL-6, we assessed 
the amounts of IL-6 released by CH12F3 treated 
with the APE1 inhibitors with particular attention 
to the APX3330 inhibitor. As shown in Figure 4A, 
CH12F3 release a discrete amount of IL-6 both 
under unstimulated or stimulated condition. While 
pretreatment with compound #3 was ineffective on 
IL-6 expression, incubation with APX3330 
inhibitor strongly reduced the levels of IL-6 
detected in the cell supernatants (Fig 4A and S3B). 
Use of the inhibitors in combination did not show 
any additive effects (Fig 4A and S3B). Moreover, 
as a further confirmation of the important role of 
APE1 in IL-6 production, an increased release of 
IL-6 by CH12F3 transfected with APE1WT 
expression plasmid was determined (Fig. 4B).  
To investigate whether APX3330 reduces IL-6 
expression and impact on CSR efficacy, CH12F3 
cells were induced to switch in the presence of 
increasing amounts of recombinant IL-6 added 
exogenously (doses ranging from 0.1 to 10000 
pg/ml). The percentage of IgA-positive cells (Fig. 
4C) and the concentration (ng/ml) of secreted IgA 
in APX3330-treated CH12F3 (Fig. 4D) were 
restored by addition of recombinant IL-6, reaching 
the same values as untreated cells. Thus, 
exogenously added recombinant IL-6 restored the 
ability of APX3330-treated cells to switch towards 
IgA. These data demonstrate that the role of APE1 
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endonuclease activity in CSR is mainly associated 
with the DNA recombination process, while the 
redox function plays an essential, though indirect, 
role through modulation of IL-6 expression.  
 
In vivo effect of APX3330 on T-independent B 
cell response to TNP-Ficoll immunization 
IgA class switching occurs via both T-cell-
dependent and T-cell-independent pathways, and 
the antibody targets both pathogenic and 
commensal microorganisms. To investigate the in 
vivo effect of APE1 inhibition on T-independent 
IgA class switching we treated mice with 50 mg/Kg 
of APX3330 the day before the immunization with 
TNP-Ficoll and every day for 7 days. At day 8, the 
blood levels of anti-TNP IgG, IgM and IgA were 
evaluated by ELISA assay. As shown in Figure 5, 
treatment with the APX3330 did not affect the 
serum level of IgG3 but increased the amount of 
anti-TNP specific IgM and reduced the amount of 
anti-TNP specific IgA.  
 
Discussion 
This work was undertaken to evaluate the 
relative contribution of the endonuclease- and the 
redox-activities of APE1, a central player in the 
BER pathway, in CSR.  
BER enzymes play a central and critical role in 
controlling the physiologic function of the immune 
system under normal and genotoxic conditions, 
such as those represented by chemotherapy and 
radiotherapy regimens. In antigen-stimulated B 
cells, both SHM and CSR provide diversification 
of the variable regions of immunoglobulin heavy 
and light chain genes and diversification of the 
heavy chain constant region. These two antibody 
maturation mechanisms require AID, which 
deaminates DNA cytosines to uracils at transcribed 
V- and switch S-regions. Uracil in DNA can be 
detected and repaired by the glycosylase UNG2-
dependent BER pathway. APE1, through its DNA 
repair AP-endonuclease activity, is responsible for 
the introduction of DNA nicks a prerequisite for the 
repair of the abasic sites generated by glycosylase 
action on damaged DNA. Despite several uracil 
glycosylases being present in mammals, APE1 is 
the only AP-endonuclease although a weak 
endonuclease activity has been recently identified 
for APE2 (16, 34, 35). While APE1 endonuclease 
activity is important for CSR, it is dispensable for 
SHM and AID-induced DNA breaks (5). Besides 
APE1 and UNG2, all the other BER enzymes 
effectively respond to the uracil removal process 
(36). The role of BER enzymes in SHM and CSR 
strongly depends on cross-talk between each single 
protein partner and is finely tuned by the 
expression level of each partner and by specific 
regulated posttranslational modifications, such as 
phosphorylation of Ser38 in AID protein (3, 4). 
Emerging evidence demonstrates that the protein 
interactome and different post-translational 
modifications occurring on the APE1 N-terminal 
domain are a major mechanism to fine-tune and 
differentiate APE1 activities (7, 15). These 
properties will deserve additional studies to fully 
understand the role of BER in CSR and SHM.  
As mentioned, while the role of APE1 
endonuclease activity in the CSR process is 
established, a role for APE1 in regulating the CSR 
through its function as a redox-transcriptional 
coactivator is still unknown. Therefore, we here 
evaluated the role of the APE1 redox activity in 
CSR of B cells in comparison to the DNA repair 
endonuclease activity by using a combination of 
specific small molecules inhibition and genetic 
approaches.  
We confirmed that the endonuclease function of 
APE1 is an important, but not unique, determinant 
for IgA-class switch recombination. We also 
provided evidence that the redox function of the 
protein plays an important role in regulating CSR 
through the IL-6 signaling pathway and proper IgA 
expression. A relationship between APE1 and IL-6 
secretion has been previously established through 
APE1’s redox regulation of NF-B and AP1 
transcription factors, promoting IL-6 expression 
(24, 37). Furthermore, IL-6 itself was reported to 
induce cytoplasmic translocation of APE1 
followed by its secretion and subsequent 
feedforward loop as a mediator of the cellular 
response by inducing IL-6 production and 
secretion (38).  However, we cannot exclude that 
the redox function of APE1 may influence the CSR 
of CH12F3 cells through additional IL-6 
independent mechanisms, and further studies are 
required to address this issue.  
In conclusion, we determined that both the 
endonuclease and redox activities are required for 
the optimal antibody diversification of the CH12F3 
and, more importantly, those specific APE1 
inhibitors can influence the isotype switching both 
in in vitro and in vivo settings. Our findings open 
new clinical perspectives for the use of APE1 redox 
inhibitors as novel anti-inflammatory compounds, 
in light of the fact that APX3330 is currently 
completing phase I clinical trials (39). In fact, 
antibody diversification is essential for the immune 
system to mount protective humoral response 
through the generation of secondary IgG, IgA and 
IgE isotypes that have the same antigen specificity 
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as IgM and IgD, but different effector functions. 
Indeed, by binding to specific Fc receptors, 
secondary isotypes can differently activate innate 
immune effector cells promoting pathogens 
opsonization and activation of the complement 
system with a different extent.  
Clinically, the levels of serum 
immunoglobulins are often increased in cancer 
patients, mirroring specific pro- or anti-
inflammatory response (40).  In particular, the 
precise role of IgA in cancer is still controversial. 
It is commonly believed that the IgA switching 
assumes a pro-tumor connotation due to the 
intrinsic immunosuppressive activities of IgA. 
Indeed, this class of Ig is a less potent opsonin and 
a weak activator of complement cascade as well as 
of the ADCC-mediated activity of the NK cells 
compared to IgG. Therefore, it can be speculated 
that the skew toward IgA weakens of the anti-
tumor immune response against a specific antigen 
compared to that induced by IgGs. Several reports 
document that increased concentrations of IgA in 
the secretion, as well as a higher expression of IgA 
in serum from patients with cancer, correlates with 
a poor prognosis (41). Very recently, high 
frequency of IgA1-positive tumor cells was found 
in tissue microarrays of esophagus, colon, testis, 
lung, breast, bladder and ovarian cancer. IgA1 was 
observed in the cytoplasm and the plasma 
membrane. A correlation was found between intra-
tumor IgA1 and poor overall survival in a large 
cohort of bladder cancer patients (42). For these 
reasons, the potential to control the skewing toward 
IgA could represent a novel and intriguing 
pharmacological approach to influence the 
humoral response in the management of the 
disease.  
The inhibitor of the APE1 redox activity, 
APX3330, is currently completing phase I clinical 
trials for safety and recommended phase II dose-
finding for future oncological clinical trials. Our 
results shed light on a novel effect of APX3330 in 
the control of cancer growth by potentially 
modulating the IgA CSR process. Further studies 
will be therefore of great interest in providing 
avenues for targeting APE1 in many diseases that 
are linked to inflammation. 
 
Experimental procedures 
 
Reagents  
Anti-mouse CD40 and anti-mouse IgA-FITC 
conjugated were from Becton Dickinson. Anti-
mouse IgA-PE conjugated, anti-mouse CD19-
APC, anti-mouse-IgG2a were from eBiosciences. 
APX3330 was from Sigma-Aldrich (E8534) (21) 
and compound 3 was a kind gift from (David 
Maloney from NIH) (18). Recombinant murine IL-
4, TGF- and IL-6 were from Peprotech. 
 
Cell culture and class switch recombination 
assay (CSR) 
CH12F3 cells, gently gifted by T. Honjo, were 
cultured in RPMI 1640 medium supplemented with 
10% fetal bovine serum, glutamine, 
penicillin/streptomycin and 50 M -
mercaptoethanol. CH12F3 containing two (+/+/) 
and zero copies of APE1 (//) have been 
described previously (16). To induce class switch 
recombination, 5x104 cell/ml were seeded in 
presence of 1 g/ml anti-CD40 antibody (Becton 
Dickinson, clone HM40-3), 5ng/ml of IL-4 and 0.5 
ng/ml di TGF- (CIT) and grown for 72h. Cells 
cultured in both CIT(-) and CIT(+) conditions were 
stained with fluorochrome-conjugated anti-mouse 
CD19 and anti-mouse IgA antibody and analyzed 
on FACScalibur. CSR efficiency was determined 
as the percentage of CD19/IgA-double positive 
cells.  
In experiments with the inhibitors, CH12F3 
cells were pre-incubated with 50 M or 0.2M of 
#3 for 1 hour, then switching stimuli were added to 
the cells without washing. 
 
Cell viability and proliferation assay  
Live and dead CH12F3 cells were evaluated by 
trypan blue exclusion test. Trypan blue-excluding 
cells were counted in a hemocytometer in four 
randomly selected fields and averaged counts were 
reported. The cellular death was detected using the 
Annexin V/PI double staining kit (eBiosciences). 
1×105 cells were first stained with 2.5µl Annexin 
V-FITC and then 5µl propidium iodide was added 
into cell suspension in turn. The cell suspension 
was incubated at room temperature for 10 minutes, 
and the apoptosis rate was detected by flow 
cytometry on FACScalibur.  
Cell viability was measured by using the CellTiter-
Glo® Luminescent Cell Viability Assay (Promega) 
on cells grown in 96-well plates after different 
treatments. Upon treatment, the CellTiter-Glo® 
Reagent was added to each well and the plates were 
incubated for an additional 2 h at 37 °C. Then, 
absorbance was measured at 490 nm by using a 
multiwell plate reader. The values were 
standardized to wells containing media alone. 
 
AP-site incision assays 
APE1 endonuclease activity was monitored 
using CH123F3 cell extracts as follows (6, 23). 
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Briefly, enzymatic reactions were carried out in a 
final volume of 10 µl using 8 ng of cell extracts in 
a buffer containing 50 mM Tris-HCl pH 7.5, 50 
mM KCl, 10 mM MgCl2, BSA (1 μg ml-1), and 1 
mM DTT. Extracts were incubated for 15 min, at 
37 °C, with 100 nM of double-stranded 26-mer 
abasic DNA substrate containing a single 
tetrahydrofuranyl artificial AP site at position 14, 
which is cleaved to a 14-mer in the presence of AP 
endonuclease activity (23). The double-strand 
DNA was obtained by annealing a 5ʹ-DY-782-
labeled oligonucleotide 5ʹ-
AATTCACCGGTACCFTCTAGAATTCG-3ʹ 
(where F indicates the tetrahydrofuran residue), 
with an unlabeled complementary sequence 
5ʹ-CGAATTCTAGAGGGTACCGGTGAATT-3ʹ. 
Reactions were halted by addition of formamide 
buffer (96% formamide, 10 mM EDTA and Gel 
Loading Buffer 6× (Fermentas)), separated onto a 
20% (w/v) denaturing polyacrylamide gel and 
analyzed on an Odyssey CLx scanner (Li-Cor 
Biosciences). The percentage of substrate 
converted to the product was determined using the 
ImageStudio software (Li-CorBiosciences). 
 
Antibodies and western blotting analysis 
For western blotting analyses, whole cell lysates 
were prepared and 20 µg of proteins were resolved 
on 12% SDS–PAGE, transferred onto 
nitrocellulose membranes (SIGMA) and probed 
with antibodies for APE1 (13B8E5C2, Novus) 
(1:1000). Data normalization was performed by 
using monoclonal anti-actin (Sigma-Aldrich) as 
indicated. The corresponding secondary antibodies 
labeled with IR-Dye (anti-rabbit IgG IRDye 680 
and anti-mouse IgG IRDye 800) were used. 
Detection and quantification were performed with 
the Odyssey CLx Infrared imaging system (LI-
COR GmbH, Germany). The membranes were 
scanned in two different channels using an 
Odyssey IR imager; protein bands were quantified 
using Odyssey software (Image Studio 5.0). 
 
ELISA assays 
The concentration of IgA in cell supernatants 
was assessed by a home-made sandwich ELISA. 
Briefly, 96-well flat-bottom polystyrene plates 
(Corning) were coated with affinity-purified anti-
mouse IgA (SouthernBiotech) at the final 
concentration of 2 mg/mL. After 1 h incubation at 
37°C, plates were washed with 0.05% Tween 20 in 
PBS and blocked with 1% bovine serum albumin 
in PBS for 1 h at RT. 100 mL of cell supernatants 
or of opportunely diluted mouse sera were added to 
Ab-coated wells. Purified mouse IgA (BD 
PharMingen) was used as a standard. After o/n 
incubation at 4°C, plates were washed and optimal 
concentration of horseradish peroxidase-
conjugated goat anti-mouse IgA (SouthernBiotech; 
1:2000) was added. Next, plates were incubated for 
1 h at RT and washed before the addition of 
tetramethylbenzidine substrate solution (Sigma-
Aldrich). The reaction was stopped with 2 mol/L 
sulfuric acid and absorbance was measured at 450 
nm. 
The levels of IL-6 in the supernatants were 
measured using a commercially available ELISA 
kit (Biosciences) following the manufacturer’s 
instructions. 
 
Transient transfection and cellular treatments  
CH12F3, CH12F3 APE1+/+/ and CH12F3 
APE1// cells were transfected with pEGFP-N2 
plasmids encoding for the APE1 wild-type or 
mutant protein using the Neon transfection system 
(Invitrogen). Briefly, 1.5 x 105 cells mixed with 
0.5ng of the plasmid of interested in 10l of buffer 
R were electroporated at 1500V and 30ms. Cells 
were firstly recovered in antibiotic-free medium 
and after 2 hours were induced to CSR in presence 
of G418 selection. After 72 h cells were harvest and 
CSR efficiency was determined as the percentage 
of GFP/IgA-double positive cells.  
 
In vivo T-independent immunization assay 
All animal experiments were approved by the 
Indiana University School of Medicine 
Institutional Animal Care and Use Committee. 
Animals were maintained under pathogen-
free conditions and a 12-hour light-dark cycle. 
Wild-type C57BL/6 mice, 6–8 weeks of age, were 
purchased from Jackson Laboratory (Bar Harbor, 
ME).  
Mice were immunized intraperitoneally with 25 
μg of TNP(65)-AECM-Ficoll (BIOSEARCH 
Technologies, Petaluma CA) at day 1. Antigen was 
diluted in PBS and injected in a final volume of 
200μL of PBS. At days 0, 1, 2 ,3, 4, 5, 6, 7 mice 
received 50 mg/kg APX3330 intraperitoneally. 
Control mice were injected with the same volume 
of PBS. On day 8 after immunization, mice were 
sacrificed. Blood was taken by cardiac puncture 
and separated sera were frozen at -20°C until use. 
Four mice 2 months-old were used per group. 
For serum Ig detection, ELISA plate was coated 
overnight at 4°C with 5μg/ml TNP(30)-BSA 
(BIOSEARCH Technologies, Petaluma CA) in 
0.05M carbonate buffer (pH9.6). The plate was 
washed three times with 0.05% Tween 20 in PBS 
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and quenched for 1 hour with PBS-BSA (1%) at 
37°C.  
Each serum obtained from immunized and control 
mice was diluted in PBS-1% BSA (2μl of sera in 
1ml of PBS). 100μl of diluted sera were plated for 
1 h at 37°C and then, after washing, HRP-
conjugated anti-mouse IgM, IgA or IgG3 
(Biolegend) diluted in PBS-1% BSA was added for 
1h at 37°C. The plate was developed by adding 100 
μL of room temperature TMB Sure Blue reagent 
(SIGMA) per well and the reaction was stopped 
adding 100 μL of TMB Stop Solution. Absorbance 
was read at 450 nm 
 
Statistical analyses 
Results are presented as mean ± SD and data 
analysis was performed with the Prism GraphPad 
Software. For comparisons between 2 groups 
unpaired and paired Student’s t-tests were used. 
When multiple comparisons were necessary, data 
were analyzed with the one-way ANOVA test and 
the Bonferroni correction was used as post hoc 
analysis. In all tests, p values < 0.05 were 
considered statistically significant. *p<0.05 
**p<0.005 ***p<0.001 
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Table 1. Effectiveness of different doses of #3 and APX3330 in reducing IgA switching of CH12F3 
cells. 
 
 
 
 
Type of Inhibitor  #3   APX3330  
 
Dose 0.04M 0.2M 1M 2.5M 12.5M 50M 
% of IgA reduction 5%2.6 12%1.9 25%5.9 0.5%2.5 7%3.5 31%8 
 
 
Figure Legends 
 
Figure 1. Different APE1 functions in mammalian cells involve independent subdomains. 
 
Figure 2. APE1 inhibitors, APX3330 and #3, reduced class switch recombination in CH12F3 treated 
cells. 
Representative dot plots (A), percentages of CD19/IgA double-positive cells (B), and amounts of released IgA 
(C) of CH12F3 under CIT(-) or CIT(+) conditions in absence or in presence of 50μM APX3330, 0.2μM #3 or 
both. Data are representative of 3 independent experiments. *p<0.05 **p<0.005 ***p<0.001 ns, not 
significant. (D) Live (trypan negative) and dead (trypan positive) cells evaluated by trypan blue exclusion after 
72h of culture under CIT(-) or CIT(+) condition in presence of indicated inhibitors. (E) Percentages of viable, 
early apoptotic, late apoptotic and necrotic CH12F3 cells measured by Annexin/PI staining. Data are 
representative of 2 independent experiments performed in triplicate. 
 
Figure 3. Re-expression of APE1WT but not APE1C65S or APE1E96A mutant forms restore the ability of 
APE1-null CH12F3 cells to undergo isotype switching.  
Representative dot plots (A), percentages of CD19/IgA double-positive cells (B), and amounts of released IgA 
(C) by switching CH12F3 APE1+/+/Δ and CH12F3 APE1Δ/Δ/Δ cells under CIT(-) and CIT(+) conditions. 
Representative dot plots (D), percentages of GFP/IgA double-positive cells (E) and amounts of released IgA 
(F) by CH12F3 APE1+/+/Δ transfected with empty vector or with GFP-APE1WT, APE1C65S or APE1E96A mutant 
forms and induced toward IgA switching. Representative dot plots (G), percentages of GFP/IgA double-
positive cells (H) and amounts of released IgA (I) by CH12F3 APE1Δ/Δ/Δ transfected with empty vector, GFP-
APE1WT, APE1C65S or APE1E96A mutant forms and induced towards IgA switching. Data are representative of 
4 independent experiments. *p<0.05 **p<0.005 ***p<0.001 ns, not significant. 
 
Figure 4. APX3330 impairs the production of IL-6 that is crucial for the optimal CSR.  
(A) Levels of secreted IL-6 in the supernatants of CH12F3 cells under CIT(-) or CIT(+) conditions in presence 
or absence of APE1 inhibitors. (B) IL-6 detection in supernatants of not transfected or CH12F3 cells 
transfected with empty vector or with GFP-APE1WT, APE1C65S or APE1E96A undergoing CSR. Data in panel A 
and panel B are representative of 3 independent experiments. (C) Percentages of CD19/IgA double-positive 
cells and (D) ng/ml of released IgA by switching CH12F3 cells untreated, pre-treated with APX3330 or pre-
treated with APX3330 and induced to CSR in presence of increasing amounts of exogenous recombinant IL-
6 (rIL-6) ranging from 0.1 to 10000pg/ml. Data are representative of 3 independent experiments and 
comparison were performed between cells treated with APX3330 versus cells treated with APX330 in presence 
of IL-6. *p<0.05 **p<0.005 ***p<0.001. 
 
Figure 5. In vivo effect of APX3330 on T-independent B cell response to TNP-Ficoll immunization. 
APX3330 treated mice (50mg/Kg) and control mice were immunized with TNP-Ficoll and the levels of 
specific anti-TNP IgM, IgG3 and IgA were evaluated in the peripheral blood 1 week after immunization. 
*p<0.05 **p<0.005 ns, not significant. 
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Figure 2.  APE1 inhibitors, APX3330 and #3, reduced class switch recombination in CH12F3 treated 
cells. Representative dot plots (A), percentages of CD19/IgA double-positive cells (B), and amounts of relea-
sed IgA (C) of CH12F3 under CIT(-) or CIT(+) conditions in absence or in presence of 50μM APX3330, 0.2μM 
#3 or both. Data are representative of 3 independent experiments. *p<0.05 **p<0.005 ***p<0.001 ns, not 
significant. (D) Live (trypan negative) and dead (trypan  positive) cells evaluated by trypan blue exclusion 
after 72h of culture under CIT(-) or CIT(+) condition in presence of indicated inhibitors. (E) Percentages of 
viable, early apoptotic, late apoptotic and necrotic CH12F3 cells measured by Annexin/PI staining. Data are 
representative of 2 independent experiments performed in triplicate. 
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Figure 3. Re-expression of APE1WT but not APE1C65S or APE1E96A mutant forms restore the abili-
ty of APE1-null CH212F3 cells to undergo isotype switching. Representative dot plots (A), 
percentages of CD19/IgA double-positive cells (B), and amounts of released IgA (C) by switching 
CH12F3 APE1+/+/Δ and CH12F3 APE1Δ/Δ/Δ cells under CIT(-) and CIT(+) conditions. Representative dot 
plots (D), percentages of GFP/IgA double-positive cells (E) and amounts of released IgA (F) by 
CH12F3 APE1+/+/Δ transfected with empty vector or with GFP-APE1WT, APE1C65S or APE1E96A mutant 
forms and induced toward IgA switching. Representative dot plots (G), percentages of GFP/IgA 
double-positive cells (H) and amounts of released IgA (I) by CH12F3 APE1Δ/Δ/Δ transfected with empty 
vector, GFP-APE1WT, APE1C65S or APE1E96A mutant forms and induced towards IgA switching.  Data 
are representative of 4 independent experiments. *p<0.05 **p<0.005 ***p<0.001 ns, not significant.
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Figure 4. APX3330 impairs the production of IL-6 that is crucial for the 
optimal CSR. (A) Levels of secreted IL-6 in the supernatants of CH12F3 cells 
under CIT(-) or CIT(+) conditions in presence or absence of APE1 inhibitors. 
(B) IL-6 detection in supernatants of not transfected or CH12F3 cells 
transfected with empty vector or with GFP-APE1WT, APE1C65S or APE1E96A 
undergoing CSR. Data in panel A and panel B are representative of 3 indepen-
dent experiments. (C) Percentages of CD19/IgA double-positive cells and (D) 
ng/ml of released IgA by switching CH12F3 cells untreated, pre-treated with 
APX3330 or pre-treated with APX3330 and induced to CSR in presence of 
increasing amounts of exogenous recombinant IL-6 (rIL-6) ranging from 0.1 to 
10000pg/ml. Data are representative of 3 independent experiments and com-
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Figure 5. In vivo effect of APX3330 on T-independent B cell response to TNP-Ficoll immu-
nization. APX3330 treated mice (50mg/Kg) and control mice were immunized with TNP-Ficoll 
and the levels of specific anti-TNP IgM, IgG3 and IgA were evaluated in the peripheral blood 1 
week after immunization. *p<0.05 **p<0.005 ns, not significant.
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